Sabby Management LLC Stake in Sarepta Therapeutics INC (SRPT) Upped by $39.92 Million

July 17, 2017 - By Vivian Currie

Investors sentiment decreased to 1.07 in Q4 2016. Its down 0.45, from 1.52 in 2016Q3. It dropped, as 42 investors sold SRPT shares while 46 reduced holdings. 39 funds opened positions while 55 raised stakes. 38.63 million shares or 7.09% less from 41.57 million shares in 2016Q3 were reported. Blackrock invested in 117,536 shares or 0% of the stock. First Allied Advisory invested 0.01% in Sarepta Therapeutics Inc (NASDAQ:SRPT). Schwab Charles Invest Management holds 0.01% in Sarepta Therapeutics Inc (NASDAQ:SRPT) or 194,108 shares. Jpmorgan Chase Co reported 0% stake. Granite Point Capital Management Limited Partnership invested 1.31% in Sarepta Therapeutics Inc (NASDAQ:SRPT). Jefferies Gp Ltd Liability accumulated 839,342 shares or 0.13% of the stock. Essex Invest Limited Liability Company owns 0.05% invested in Sarepta Therapeutics Inc (NASDAQ:SRPT) for 11,063 shares. Highland Limited Partnership has 0.11% invested in Sarepta Therapeutics Inc (NASDAQ:SRPT). Moreover, J Goldman LP has 0.18% invested in Sarepta Therapeutics Inc (NASDAQ:SRPT) for 99,900 shares. Raymond James Fincl Svcs Advsr has invested 0% in Sarepta Therapeutics Inc (NASDAQ:SRPT). Ig Invest Mgmt Limited invested in 0.01% or 40,000 shares. Sphera Funds Mgmt reported 398,047 shares. Dupont Mngmt Corporation reported 0.01% in Sarepta Therapeutics Inc (NASDAQ:SRPT). Cadian Management Limited Partnership has invested 0.51% in Sarepta Therapeutics Inc (NASDAQ:SRPT). Quantitative Investment Mgmt Limited Liability Co holds 197,400 shares or 0.14% of its portfolio.

Hal Mintz increased its stake in Sarepta Therapeutics Inc (SRPT) by 275.7% based on its latest 2016Q4 regulatory filing with the SEC. Sabby Management Llc bought 1.48M shares as the company’s stock rose 22.49% with the market. The hedge fund run by Hal Mintz held 2.01M shares of the health care company at the end of 2016Q4, valued at $55.27 million, up from 536,282 at the end of the previous reported quarter. Sabby Management Llc who had been investing in Sarepta Therapeutics Inc for a number of months, seems to be bullish on the $1.92B market cap company. The stock decreased 0.85% or $0.3 during the last trading session, reaching $34.95. About 1.41 million shares traded or 7.63% up from the average. Sarepta Therapeutics Inc (NASDAQ:SRPT) has risen 96.82% since July 17, 2016 and is uptrending. It has outperformed by 80.12% the S&P500.

Sabby Management Llc, which manages about $835.79M and $1.72 billion US Long portfolio, decreased its stake in Clovis Oncology Inc (Put) by 1,671 shares to 420 shares, valued at $1.87 million in 2016Q4, according to the filing. It also reduced its holding in Ionis Pharmaceuticals Inc (Call) by 1,117 shares in the quarter, leaving it with 1,054 shares, and cut its stake in Sarepta Therapeutics Inc (Put).

More notable recent Sarepta Therapeutics Inc (NASDAQ:SRPT) news were published by: Nasdaq.com which released: “Sarepta Looks to Focus on Exondys 51 & DMD Pipeline in 2017” on June 30, 2017, also Globenewswire.com with their article: “Sarepta Therapeutics Appoints Douglas S. Ingram as President and Chief …” published on June 28, 2017, Globenewswire.com published: “Sarepta Therapeutics and Genethon Announce a Gene Therapy Research …” on June 21, 2017. More interesting news about Sarepta Therapeutics Inc (NASDAQ:SRPT) were released by: Marketwatch.com and their article: “Sarepta Therapeutics names new CEO” published on June 28, 2017 as well as Nasdaq.com‘s news article titled: “SRPT Makes Bullish Cross Above Critical Moving Average” with publication date: July 13, 2017.

Sarepta Therapeutics Inc (NASDAQ:SRPT) Ratings Coverage

Among 24 analysts covering Sarepta Therapeutics (NASDAQ:SRPT), 17 have Buy rating, 1 Sell and 6 Hold. Therefore 71% are positive. Sarepta Therapeutics had 65 analyst reports since August 5, 2015 according to SRatingsIntel. As per Friday, October 28, the company rating was maintained by RBC Capital Markets. Jefferies downgraded Sarepta Therapeutics Inc (NASDAQ:SRPT) on Friday, April 29 to “Underperform” rating. As per Wednesday, August 5, the company rating was maintained by Roth Capital. The stock of Sarepta Therapeutics Inc (NASDAQ:SRPT) has “Outperform” rating given on Monday, September 19 by William Blair. The stock of Sarepta Therapeutics Inc (NASDAQ:SRPT) has “Market Perform” rating given on Thursday, April 21 by William Blair. Roth Capital maintained the stock with “Buy” rating in Thursday, September 3 report. Wedbush upgraded it to “Outperform” rating and $36 target in Tuesday, June 7 report. On Friday, December 16 the stock rating was maintained by RBC Capital Markets with “Outperform”. On Wednesday, April 20 the stock rating was initiated by Janney Capital with “Neutral”. On Monday, September 19 the stock rating was upgraded by Janney Capital to “Buy”.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.